Regarding survival, although not statistically significant, it is important to note that 16.3% of the deceased had HER2-positive GC and that almost 75% of the HER2-positive patients died, which together with the data on metastasis and advanced stages would corroborate the poor prognosis associated with this type of GC, although a clear consensus is still lacking [1,5,6,19,36,38,48]. Here, ERBB2 is linked to gastric cancer.